Disclosed herein are compositions that inhibit adipogenesis of a fibro/adipogenic precursor (FAP) cell and methods relating to treating, preventing, reducing, and/or inhibiting a muscular degenerative condition a muscular degenerative condition comprising administering said inhibitors.

The present invention relates to a solid pharmaceutical formulation comprising misoprostol or a pharmaceutically acceptable salt thereof. In particular, the invention relates to a dispersible tablet comprising misoprostol or a pharmaceutically acceptable salt thereof.

The present disclosure provides methods and compositions useful for the prophylactic and therapeutic amelioration and treatment of infections caused by Gram-negative bacteria, including Pseudomonas aeruginosa. The disclosure further provides compositions and methods of incorporating and utilizing lysin polypeptides of the present disclosure for augmenting the efficacy of antibiotics generally suitable for the treatment of Gram-negative bacterial infection.

The invention relates to methods of sonodynamic therapy comprising the co-administration of a microbubble-chemotherapeutic agent complex together with a microbubble-sonosensitiser complex. It further relates to pharmaceutical compositions comprising these complexes and their use in methods of sonodynamic therapy and/or sonodynamic diagnosis. Such methods find particular use in the treatment of cancer, e.g. pancreatic cancer.

The present invention relates to a ligand-SIFA-chelator conjugate, comprising, within in a single molecule three separate moieties: (a) one or more ligands which are capable of binding to a disease-relevant target molecule, (b) a silicon-fluoride acceptor (SIFA) moiety which comprises a covalent bond between a silicon atom and a fluorine atom, and (c) one or more chelating groups, optionally containing a chelated nonradioactive or radioactive cation.

This disclosure relates generally to methods and agents for treating acute neuroinflammatory injury, such as stroke (e.g. ischemic stroke or hemorrhagic stroke), hypoxic-ischemic brain injury, traumatic brain injury, subarachnoid hemorrhage and intracerebral hemorrhage. In particular, the present disclosure relates to the use of CD14 antagonist antibodies for treating acute neuroinflammatory injury.

Provided herein is a method for identifying cytotoxic T cell activity due to cancer immunotherapy in a subject. In some embodiments, the method comprises administering an effective amount of a tracer for positron emission tomography (PET) or single photon emission computed tomography (SPECT) to a subject receiving a cancer immunotherapy, wherein the tracer comprises an antibody or antigen-binding fragment thereof that specifically binds to a luminal domain of a lymphocytic granule-associated molecule (LGAM) labeled with a PET or SPECT detectable moiety, and detecting the signal of the tracer by PET or SPECT imaging to identify the cytotoxic T cell activity due to immune therapy for the cancer in the subject. In several embodiments, the antibody or antigen binding fragment specifically binds to the luminal domain of CD107a.

Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.

Disclosed herein are compositions comprising a CT20 peptide and methods of using the disclosed compositions to treat cancers expressing chaperonin containing TCP (CCT).

Biodegradable Periodic Mesoporous Organosilica (BPMO) nanomaterials and methods of making BPMOs loaded with Neutron Capture Agents are disclosed herein. Consequently, the BPMOs loaded with Neutron Capture Agents provide a method of treating cancer, immunological disorders and other disease by utilizing a Neutron Capture Therapy modality.